Physician profile
Nicholas C Hollenkamp
NPI 1891792149
$10,163.61
in general payments reported to CMS, 2019-2025
25 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 85% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,166 · 2020: $1,764 · 2021: $1,095 · 2022: $1,136 · 2023: $1,273 · 2024: $1,324 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,905 · Education: $97.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,904.98 |
| Education | $97.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,175.89 | 2019-2022 | |
| Aerin Medical INC. | $2,031.02 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,773.16 | 2019-2025 | Dupixent |
| Medtronic USA, INC. | $1,182.13 | 2019-2020 | |
| Spirair, INC. | $749.52 | 2024-2025 | Septalign |
| Medtronic, INC. | $538.02 | 2021-2025 | Propel |
| Glaxosmithkline, LLC. | $396.61 | 2022-2025 | Nucala |
| Medline Industries LP | $362.29 | 2019 | |
| Genzyme Corporation | $285.55 | 2020-2025 | |
| Optinose US, INC. | $206.34 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2025 | Tezspire |
| Acclarent, INC | $65.49 | 2019-2021 | |
| Amgen INC. | $40.93 | 2025 | Tezspire |
| Hologic Sales and Service, LLC | $35.45 | 2023 | Coolseal Generator |
| Davol INC. | $25.15 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.91 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $20.34 | 2025 | |
| Shire North American Group INC | $19.26 | 2019 | |
| Merck Sharp & Dohme LLC | $18.28 | 2023 | |
| Inspire Medical Systems, INC. | $17.34 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $16.61 | 2024 | Voquezna |
| Pfizer INC. | $16.25 | 2019 | |
| Kaleo, INC. | $13.92 | 2022 | |
| Abbvie INC. | $13.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Hollenkamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.